CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 405 enrolled
Drug / intervention
Dymista Nasal Spray +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01794741
NCT01794741Phase 3Completed

Randomized Trial of the Safety of Dymista Nasal Spray and Fluticasone Propionate Nasal Spray in Children Ages >4 Years to <12 Years With Allergic Rhinitis

Meda Pharmaceuticals·interventional·Posted Feb 20, 2013·Updated Mar 31, 2015

In Brief

A Phase 3 clinical trial evaluating Dymista Nasal Spray and Fluticasone propionate nasal spray for Allergic Rhinitis. Completed, enrolled 405 participants across 41 sites.

Detailed Summary

This is a 3 month safety study of Dymista Nasal spray in children aged 4 to 11 years with allergic rhinitis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 20, 2013
Enrollment StartFeb 1, 2013
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 13.4 years ago

Interventions

Dymista Nasal Spraydrug

Fluticasone propionate nasal spraydrug